IRVINE, Calif., Dec. 9, 2005 (PRIMEZONE) -- "In the continued race for development of important new drugs, treatments and devices, protecting intellectual property assets within the biotechnology space is playing a decidedly vital role," said SmallCap Sentinel analyst, D.R. Clark. "In the fast-paced, R&D-laden world of biotechnology, protecting what you have becomes an imperative as work continues toward critical approvals leading to marketing and revenue generation."
"For companies such as Callisto Pharmaceuticals (AMEX:KAL), which recently announced the formation of a Department of Intellectual Property to spearhead growth of the Company's pipeline of new drug candidates, clearly this has become a big part of their strategy," said Clark. "Several recent announcements by biotech firms have focused on broadening patent protection. The baby-boomer market is clamoring for effective treatments and cures for our society's most dreaded ailments and drug companies are growing more and more vigilant about their valuable products and other assets."
The informational report "The Silver Tsunami: Baby Boomers & Biotech Breakthroughs" has been made available by financial courier StockUpTicks at: www.SmallCapSentinel.com
The report addresses issues regarding emergent biotechnology potentially affecting drug makers such as Eli Lilly (NYSE:LLY), Neurogen Corporation (Nasdaq:NRGN), and Gene Logic (NASDAQ:GLGC).
A detailed informational report regarding Callisto Pharmaceuticals is available free to the public at the following link: http://www.trilogy-capital.com/kal_summary.aspx
Statements made herein contain forward-looking statements and are subject to significant risks and uncertainties that affect results. SmallCap Sentinel and StockUpTicks.com are properties of Market Pathways Financial Relations Inc. (MP). MP provides no assurance as to the subject company's plans or ability to effect any proposed actions and cannot project capabilities, intent, resources, or experience.
All information contained herein is based upon sources believed to be reliable but no representation is made as to its accuracy or completeness. This report is neither a solicitation to buy, nor offer to sell securities but is rather a paid advertisement provided for information purposes only and should not be used as the basis for any investment decision. MP is not an investment advisor and this report is not investment advice. MP has been paid $1,500 by Callisto for preparation and distribution of this report and other advertising services. This constitutes a conflict of interest as to MP's ability to remain objective in its communication regarding the subject companies.